Summary
Stryker Corporation's second-quarter 2020 report reveals a significant impact from the COVID-19 pandemic, leading to a substantial decline in net sales and profitability compared to the prior year. Net sales decreased by 24.3% to $2.76 billion for the quarter and 11.4% for the first six months of the year. This downturn was primarily driven by the postponement of elective medical procedures, which affected all business segments, particularly Orthopaedics and Neurotechnology and Spine. Despite these challenges, the company demonstrated resilience through improved cash flow from operations and strategic debt management. Operationally, the company incurred notable asset impairment charges related to an ERP system suspension and other exit costs, contributing to an operating loss for the quarter. However, excluding these and other special items, adjusted operating income and adjusted net earnings per share show a more moderate decline, reflecting the ongoing operational efficiencies and underlying business strength. The company also maintained a strong liquidity position, with increased cash and cash equivalents, and continued its strategic acquisition of Mobius Imaging and Cardan Robotics, positioning itself for future growth.
Financial Highlights
51 data points| Revenue | $2.76B |
| Cost of Revenue | $1.22B |
| Gross Profit | $1.55B |
| R&D Expenses | $233.00M |
| SG&A Expenses | $1.23B |
| Operating Expenses | $1.57B |
| Operating Income | -$20.00M |
| Net Income | -$83.00M |
| EPS (Basic) | $-0.22 |
| EPS (Diluted) | $-0.22 |
| Shares Outstanding (Basic) | 375.50M |
| Shares Outstanding (Diluted) | 375.50M |
Key Highlights
- 1Net sales declined 24.3% year-over-year to $2.76 billion for Q2 2020 due to COVID-19 related procedure deferrals.
- 2Operating income turned to a loss of $20 million for Q2 2020, compared to $613 million in Q2 2019, impacted by asset impairments and lower sales.
- 3Net earnings (loss) per diluted share was $(0.22) for Q2 2020, a significant decrease from $1.26 in Q2 2019.
- 4The company reported strong cash flow from operations of $1,211 million for the first six months of 2020, an increase from $827 million in the prior year.
- 5Total debt increased to $12,921 million as of June 30, 2020, largely due to new senior unsecured note issuances.
- 6Stryker maintained significant cash and cash equivalents, totaling $6,539 million as of June 30, 2020.
- 7The acquisition of Mobius Imaging and Cardan Robotics was completed in October 2019, integrated into the Spine business, and its purchase price allocation was finalized in 2020.